Global Epigenome Analysis Market, By Technology (Elisa, ChIP Qpcr, ChIP‐on‐Chip, Others), Components (Ethylation, Acetylation, Phosphorylation, Ubiquitylation, Sumoylation), Methods (DNA Methylation Analysis, Analysis of DNA/Protein Interactions, Chromatin Accessibility, Conformation Assays), End Users (Academic and Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations) – Industry Trends and Forecast to 2030.
Epigenome Analysis Market Analysis and Size
According to the NCI, the annual cancer death rate in the United States is 163.5 per 100,000 men and women. The International Cancer Genome Consortium (ICGC) is working to characterize tumour genomics, epigenomic changes, and transcriptomic changes. Rising prevalence of cancer, chronic diseases and the growing geriatric population all these factors are expected to drive market growth.
Data Bridge Market Research analyses that the epigenome analysis market which was USD 1.47 billion in 2022, is expected to reach USD 4.5 billion by 2030, at a CAGR of 15% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Epigenome Analysis Market Scope and Segmentation
2023 to 2030
2021 (Customizable to 2015 - 2020)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Technology (Elisa, ChIP Qpcr, ChIP‐on‐Chip, Others), Components (Ethylation, Acetylation, Phosphorylation, Ubiquitylation, Sumoylation), Methods (DNA Methylation Analysis, Analysis of DNA/Protein Interactions, Chromatin Accessibility, Conformation Assays), End Users (Academic and Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Illumina, Inc. (U.S.), Merck KGaA (Germany), QIAGEN (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Eisai Co., Ltd. (Japan), Novartis AG (Switzerland), Abcam plc (U.K.), Diagenode s.a. (U.S.), Active Motif, Inc. (U.S.), Zymo Research Corporation. (U.S.), Thermo Fisher Scientific (U.S.), Cellcentric (Germany), Syndax (U.S.), New England Biolabs (U.S.), Epizyme, Inc. (U.S.), Domainex (U.K.), Agilent Technologies, Inc. (U.S.), PerkinElmer Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), AsisChem Inc. (US), Enzo Life Sciences, Inc. (U.S.), EpiGentek Group Inc. (U.S.), BioVision Inc. (U.S.), Bio-Techne. (U.S.), Promega Corporation (U.S.), GeneTex, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.)
Epigenetics is the study of changes in gene function that occur without any changes in the DNA sequence. Several previous studies have suggested that epigenetic changes are heritable. This subproject focuses on the epigenetic mechanism of DNA methylation, which can be measured in-house using the Infinium HumanMethylation450 BeadChip or our implemented NGS-based Reduced Representation Bisulfite Sequencing (RRBS) protocol. All bioinformatics tools required for detecting differentially methylated regions in RRBS NGS data are available.
Global Epigenome Analysis Market Dynamics
- Rising research and development activities
Organizations such as the International Human Epigenome Consortium (IHEC), the National Cancer Institute (NCI), and the National Institute of Health (NIH) are influencing market growth. These organizations advocate for funding and support for research and development in epigenetics. The National Institutes of Health funds epigenetics research through a common fund epigenomics programme, which actively supports new epigenetic research around the world. Rising demand for understanding epigenetic modifications at the molecular level and developing therapeutic solutions will likely motivate these organizations to fund research and development programmes. Furthermore, initiatives such as the Epidemiology and Genomics Research Program (EGRP) provide incentives for research activities aimed at better understanding cancer causes and outcomes.
- Government Initiatives
The Encyclopedia of DNA Elements (ENCODE) project was initiated by the National Human Genome Research Institute in the United States with the goal of identifying all of the human genome sequence functional elements. The NIH-funded International Human Epigenome Consortium (IHEC) is also involved in generating and analyzing epigenomic data that epigenomic researchers can use. Most epigenetics research aims to identify treatment options for various types of tumours.
- Increasing geriatric population
A rise in the geriatric population is expected to boost market growth. According to WHO, the global population of people aged 65 and up is expected to grow from 1 billion in 2019 to approximately 1.4 billion by 2030 and 2.1 billion by 2050, with developing countries accounting for a significant increase. Aging is thought to be the greatest risk factor for cardiovascular and neurological diseases, so it is expected to increase the risk of developing these diseases. Furthermore, ageing weakens the immune system and increases the risk of contracting infectious diseases. Furthermore, the growing geriatric population in Asian countries such as China, Japan, and India, which have significant untapped potential, is expected to drive market growth during the forecast period.
- High R&D costs
High R&D costs for developing novel products and a stringent approval process are impeding market growth. Before being commercialized, the appropriate regulatory authorities must approve novel epigenetic drugs. This framework for drug approval is time-consuming and stringent. There are no clear regulatory policies in place in emerging economies such as China and India, where the diagnostic market has significant growth potential due to a large patient pool. However, a lack of skilled labour and insufficient health insurance coverage in remote areas are two major impediments to the growth of this market.
This epigenome analysis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the epigenome analysis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on the Epigenome Analysis Market
The Covid-19 pandemic had a significant impact on the epigenome analysis market growth. According to a study published in BioMed Central, epigenetic changes may play an important role in the emergence of coronavirus illness consequences. Although several epigenetic therapies are being investigated, more research is required to develop an effective vaccine and safer therapeutic options, including epigenetic treatments, to combat this viral pandemic. As a result, more epigenetics will be used in the identification of COVID-19 infection therapeutics, fueling market growth throughout the forecast period.
Epigenome Analysis Market Scope
The epigenome analysis market is segmented on the basis of technology, component, methods and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- ChIP Qpcr
- DNA Methylation Analysis
- Analysis of DNA/Protein Interactions
- Chromatin Accessibility
- Conformation Assays
- Academic and Research Institutes
- Pharmaceutical Companies
- Biotechnology Companies
- Contract Research Organizations
Epigenome Analysis Market Regional Analysis/Insights
The epigenome analysis market is analyzed and market size insights and trends are provided by country, technology, component, methods and end users as referenced above.
The countries covered in the epigenome analysis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the epigenome analysis market because of the availability of advanced healthcare facilities and continual advancements in diagnostic procedures.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the rise in the disposable income. Moreover, the growing untapped clinical needs of the patients is further anticipated to grow in the region's epigenetics market in the coming years.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The epigenome analysis market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for epigenome analysis market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the epigenome analysis market. The data is available for historic period 2011-2021.
Competitive Landscape and Epigenome Analysis Market Share Analysis
The epigenome analysis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to epigenome analysis market.
Some of the major players operating in the epigenome analysis market are:
- Illumina, Inc. (U.S.)
- Merck KGaA (Germany)
- QIAGEN (Germany)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Eisai Co., Ltd. (Japan)
- Novartis AG (Switzerland)
- Abcam plc (U.K.)
- Diagenode s.a. (U.S.)
- Active Motif, Inc. (U.S.)
- Zymo Research Corporation. (U.S.)
- Thermo Fisher Scientific (U.S.)
- Cellcentric (Germany)
- Syndax (U.S.)
- New England Biolabs (U.S.)
- Epizyme, Inc. (U.S.)
- Domainex (U.K.)
- Agilent Technologies, Inc. (U.S.)
- PerkinElmer Inc. (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- AsisChem Inc. (U.S.)
- Enzo Life Sciences, Inc. (U.S.)
- EpiGentek Group Inc. (U.S.)
- BioVision Inc. (U.S.)
- Bio-Techne. (U.S.)
- Promega Corporation (U.S.)
- GeneTex, Inc. (U.S.)
- Pacific Biosciences of California, Inc. (U.S.)
Research Methodology: Global Epigenome Analysis Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.